These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 17037949)

  • 1. Methylphenidate controlled-delivery capsules (EquasymXL, Metadate CD): a review of its use in the treatment of children and adolescents with attention-deficit hyperactivity disorder.
    Anderson VR; Keating GM
    Paediatr Drugs; 2006; 8(5):319-33. PubMed ID: 17037949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spotlight on methylphenidate controlled-delivery capsules (Equasym XL, Metadate CD) in the treatment of children and adolescents with attention-deficit hyperactivity disorder.
    Anderson VR; Keating GM
    CNS Drugs; 2007; 21(2):173-5. PubMed ID: 17284098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
    Swanson JM; Wigal SB; Wigal T; Sonuga-Barke E; Greenhill LL; Biederman J; Kollins S; Nguyen AS; DeCory HH; Hirshe Dirksen SJ; Hatch SJ;
    Pediatrics; 2004 Mar; 113(3 Pt 1):e206-16. PubMed ID: 14993578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
    Wilens TE; McBurnett K; Bukstein O; McGough J; Greenhill L; Lerner M; Stein MA; Conners CK; Duby J; Newcorn J; Bailey CE; Kratochvil CJ; Coury D; Casat C; Denisco MJ; Halstead P; Bloom L; Zimmerman BA; Gu J; Cooper KM; Lynch JM
    Arch Pediatr Adolesc Med; 2006 Jan; 160(1):82-90. PubMed ID: 16389216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A postmarketing clinical experience study of Metadate CD.
    Dirksen SJ; D'Imperio JM; Birdsall D; Hatch SJ
    Curr Med Res Opin; 2002; 18(7):371-80. PubMed ID: 12487502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dexmethylphenidate extended release: a review of its use in the treatment of attention-deficit hyperactivity disorder.
    Moen MD; Keam SJ
    CNS Drugs; 2009 Dec; 23(12):1057-83. PubMed ID: 19958043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
    Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
    Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data.
    Sonuga-Barke EJ; Swanson JM; Coghill D; DeCory HH; Hatch SJ
    BMC Psychiatry; 2004 Sep; 4():28. PubMed ID: 15458569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained-release methylphenidate: new preparations. New pharmaceutical forms: a slight advantage for a small number of children.
    Prescrire Int; 2004 Dec; 13(74):203-6. PubMed ID: 15612099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
    Wolff C; Alfred A; Lindermüller A; Rettig K; Mattejat F; Gerwe M; Slawik L; Schäuble B
    Curr Med Res Opin; 2011; 27 Suppl 2():35-44. PubMed ID: 21787126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
    Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L
    CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
    Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.
    Pliszka SR; Wilens TE; Bostrom S; Arnold VK; Marraffino A; Cutler AJ; López FA; DeSousa NJ; Sallee FR; Incledon B; Newcorn JH
    J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):474-482. PubMed ID: 29172680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y; Yang L; Stein MA; Cao Q; Wang Y
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of osmotic-controlled release oral delivery system methylphenidate HCl in adults with attention-deficit/hyperactivity disorder in Japan.
    Takahashi N; Koh T; Tominaga Y; Saito Y; Kashimoto Y; Matsumura T
    World J Biol Psychiatry; 2014 Aug; 15(6):488-98. PubMed ID: 24456065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Multilayer, Extended-Release Methylphenidate (PRC-063) in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder: A Laboratory Classroom Study.
    Childress AC; Brams MN; Cutler AJ; Donnelly GAE; Bhaskar S
    J Child Adolesc Psychopharmacol; 2020 Dec; 30(10):580-589. PubMed ID: 33090921
    [No Abstract]   [Full Text] [Related]  

  • 18. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies.
    Swanson J; Gupta S; Lam A; Shoulson I; Lerner M; Modi N; Lindemulder E; Wigal S
    Arch Gen Psychiatry; 2003 Feb; 60(2):204-11. PubMed ID: 12578439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probabilistic Markov Model Estimating Cost Effectiveness of Methylphenidate Osmotic-Release Oral System Versus Immediate-Release Methylphenidate in Children and Adolescents: Which Information is Needed?
    Schawo S; van der Kolk A; Bouwmans C; Annemans L; Postma M; Buitelaar J; van Agthoven M; Hakkaart-van Roijen L
    Pharmacoeconomics; 2015 May; 33(5):489-509. PubMed ID: 25715975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OROS methylphenidate hydrochloride for adult patients with attention deficit/hyperactivity disorder.
    McBurnett K; Starr HL
    Expert Opin Pharmacother; 2011 Feb; 12(2):315-24. PubMed ID: 21226641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.